Kuros Biosciences hit three advancements for its MagnetOS portfolio, according to a Jan. 4 news release.
The company released new data from the MAXA clinical trial which compared standalone MagnetOS to the gold standard autograft in the posterior spinal fusion approach. The study found MagnetOS had a fusion rate of 78% after one year compared to 45% with the autograft.
MagnetOS Easypack puttyputty earned FDA 510(k) clearances. MagnetOs Easypack putty can be used in any interbody spaces and cages approved for use with bone void fillers.
Magnet OS putty was also cleared by the FDA for standalone use or mixed with an autograft.